<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942020000400007</article-id>
<article-id pub-id-type="doi">10.30827/ars.v61i4.15204</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estudio comparativo de la calidad biofarmacéutica de Clonazepam 0,5 mg comercializados en el mercado peruano]]></article-title>
<article-title xml:lang="en"><![CDATA[Comparative study of the biopharmaceutical quality of Clonazepam 0.5 mg commercialized in the Peruvian market]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodriguez-Saavedra]]></surname>
<given-names><![CDATA[Lennin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moreno-Garrido]]></surname>
<given-names><![CDATA[Zoila]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aroca-Sevillano]]></surname>
<given-names><![CDATA[Diego]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional Mayor de San Marcos Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Lima ]]></addr-line>
<country>Perú</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional de Trujillo Facultad de Farmacia y Bioquímica ]]></institution>
<addr-line><![CDATA[Trujillo ]]></addr-line>
<country>Perú</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidade de São Paulo Faculdade de Ciências Farmacêuticas ]]></institution>
<addr-line><![CDATA[São Paulo ]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>61</volume>
<numero>4</numero>
<fpage>245</fpage>
<lpage>252</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942020000400007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942020000400007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942020000400007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: el Clonazepam pertenece a un grupo de medicamentos llamados benzodiazepinas. Se sabe que estos medicamentos actúan en el cerebro a través del GABA. Es un anticonvulsivante utilizado para varios tipos de ataques, incluyendo ataques miotónicos o atónicos, epilepsia fotosensible, y crisis de ausencia, aunque puede desarrollarse tolerancia. Raras veces es eficaz en ataques tónico-clónicos generalizados o parciales.  Método: el presente estudio se realizó para analizar los parámetros comparativos de control de calidad in vitro mediante la evaluación de la variación de peso, friabilidad, dureza, tiempo de desintegración y perfil de disolución entre el medicamento innovador (Rivotril®) y medicamentos multifuente que son comercializados en el mercado peruano. Para realizar el estudio comparativo, se seleccionaron tabletas de Clonazepam 0,5 mg multifuente de diferentes laboratorios comparándolos con el medicamento innovador y se evaluaron las características fisicoquímicas y biofarmacéuticas. Los ensayos farmacopeicos se evaluaron según lo establecido en la USP 42.  Resultados: los resultados permitieron establecer que todas las marcas analizadas cumplieron los criterios de aceptación establecidos en la farmacopea para cada principio activo y que el comportamiento biofarmacéutico de ellas era muy similar para ambos tipos de molécula.  Conclusiones: se estableció que todas las tabletas multifuente de Clonazepam 0,5 mg incluidos en esta investigación son bioequivalentes con la marca innovadora elegida y, por lo que permite proponer a la comunidad científica la determinación de la equivalencia biofarmacéutica como elemento de apoyo en la toma de decisiones de compra en el servicio farmacéutico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Clonazepam belongs to a group of medications called benzodiazepines. It is known that these drugs act in the brain through GABA. It is an anticonvulsant used for various types of attacks, including myotonic or atonic attacks, photosensitive epilepsy, and absence attacks, although tolerance may develop. It is rarely effective in generalized or partial tonic-clonic attacks.  Method: the present study was carried out to analyze the comparative parameters of in vitro quality control by evaluating the variation in weight, friability, hardness, disintegration time and dissolution profile between the innovative drug (Rivotril®) and multi-source drugs that are marketed in the Peruvian market. To carry out the comparative study, Clonazepam 0.5 mg multi-source tablets were selected from different laboratories comparing them with the innovative medicine and the physicochemical and biopharmaceutical characteristics were evaluated. Pharmacopoeial trials were evaluated as established in USP 42.  Results: the results made it possible to establish that all the brands analyzed met the acceptance criteria established in the pharmacopoeia for each active ingredient and that their biopharmaceutical behavior was very similar for both types of molecule.  Conclusions: it was established that all Clonazepam 0.5 mg multi-source tablets included in this research are bioequivalent with the chosen innovative brand and, therefore, allow the determination of biopharmaceutical equivalence as a support element in decision-making to be proposed to the scientific community purchase in the pharmaceutical service]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Clonazepam]]></kwd>
<kwd lng="es"><![CDATA[intercambiabilidad]]></kwd>
<kwd lng="es"><![CDATA[control de calidad]]></kwd>
<kwd lng="en"><![CDATA[Clonazepam]]></kwd>
<kwd lng="en"><![CDATA[interchangeability]]></kwd>
<kwd lng="en"><![CDATA[quality control]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Determinación de una técnica selectiva por cromatografía en capa fina para identificación de benzodiazepinas]]></source>
<year>2017</year>
<publisher-name><![CDATA[Universidad Norbert Wiener]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>FDA - Food and Drug Administration</collab>
<source><![CDATA[U.S. Food &amp; Drug Administration: Guía para la Industria: Pruebas de disolución de formas de dosificación oral sólidas de liberación inmediata]]></source>
<year>1997</year>
<publisher-name><![CDATA[Centro de Evaluación e Investigación de Drogas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>FDA - Food and Drug Administration U.S.</collab>
<article-title xml:lang=""><![CDATA[Comparability Protocols for Human Drugs and Biologics]]></article-title>
<source><![CDATA[Guidance for Industry Guidance for Industry Contains Nonbinding Recommendations]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amidon]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lennernäs]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo]]></article-title>
<source><![CDATA[AAPSj]]></source>
<year>1995</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>413-20</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fatima]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jamil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In-vitro dissolution testing for therapeutic equivalence of metronidazole immediate release tablets available in Karachi, Pakistan]]></article-title>
<source><![CDATA[Int J Pharm Sci Res]]></source>
<year>2017</year>
<volume>8</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>3133-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iriarte]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Desarrollo de Medios de Disolución Biorrelevantes para Fármacos con Problemas de Bioequivalencia]]></source>
<year>2015</year>
<page-range>1-37</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Miguel Hernández]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Segura Campos]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medicamentos Genéricos: Su Importancia Económica En Los Sistemas Públicos de Salud y La Necesidad de Estudios in Vitro Para Establecer Su Bioequivalencia]]></article-title>
<source><![CDATA[Pensamiento Actual]]></source>
<year>2017</year>
<volume>17</volume>
<numero>28</numero>
<issue>28</issue>
<page-range>119-31</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amidon]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hans]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vinod]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability]]></article-title>
<source><![CDATA[AAPS J]]></source>
<year>1995</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>413-20</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Granero]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Polache]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Absorption of Drugs after Oral Administration]]></article-title>
<source><![CDATA[Int Pharm Sci Encyclopedia]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ono]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kiyohiko]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Application of the BCS Biowaiver Approach to Assessing Bioequivalence of Orally Disintegrating Tablets with Immediate Release Formulations]]></article-title>
<source><![CDATA[European Journal of Pharmaceutical Sciences]]></source>
<year>2014</year>
<volume>64</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>37-43</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Flavian]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Commonality between BCS and TCS]]></article-title>
<source><![CDATA[International Journal of Pharmaceutics]]></source>
<year>2016</year>
<volume>509</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>35-40</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baishya]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gogoi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bordoloi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gogoi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In-vitro evaluation of two marketed brands of dexame-thasone tablets IP as per Indian pharmacopoeia]]></article-title>
<source><![CDATA[International Journal of Research in Pharmacy and Pharmaceutical Sciences]]></source>
<year>2018</year>
<volume>3</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>197-201</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Domínguez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Collares]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso racional de benzodiacepinas: hacia una mejor prescripción]]></article-title>
<source><![CDATA[Rev Urug Med Int]]></source>
<year>2016</year>
<volume>1</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>14-24</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<source><![CDATA[Farmacopea de los Estados Unidos de América, Formulario Nacional, USP, USP 42-NF 37]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Baltimore ]]></publisher-loc>
<publisher-name><![CDATA[The Pharmacopeial Convention, United Book Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalakuntla]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Veerlapati]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chepuri]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of various super disintegrants on hardness, disintegration and dissolution of medicine from dosage form]]></article-title>
<source><![CDATA[J Adv Sci Res]]></source>
<year>2010</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>15</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<collab>World Health Organization</collab>
<article-title xml:lang=""><![CDATA[Proposal to Waive the In Vivo Bioequivalence Requirements for the Model List of Essential Medicines Immediate Release, Solid Oral Dosage Forms]]></article-title>
<source><![CDATA[WHO Expert Committee On Specifications for Pharmaceutical Preparations. Fortieth Report]]></source>
<year>2006</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karmakar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Golam]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In-Vitro Comparative Evaluation of Quality Control Parameters between Paracetamol and Paracetamol/Caffeine Tablets Available in Bangladesh]]></article-title>
<source><![CDATA[Int C Pharm J Online (JOL)]]></source>
<year>2012</year>
<page-range>103-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Musa]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sule]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Gwarzo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of physicochemical properties of metronidazole tablets marketed in Zaria, Nigeria]]></article-title>
<source><![CDATA[Int J Pharm Pharm Sci]]></source>
<year>2011</year>
<volume>3</volume>
<page-range>27-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murtha]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Julian]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Radebaugh]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Simultaneous determination of pseudoephedrine hydrochloride, chlorpheniramine maleate, and dextromethorphan hydrobromide by second-derivative photodiode array spectroscopy]]></article-title>
<source><![CDATA[Journal of Pharmaceutical Sciences]]></source>
<year>1988</year>
<volume>77</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>715-8</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kostag]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Teixeira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[T De]]></given-names>
</name>
<name>
<surname><![CDATA[El Seoud]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing cellulose dissolution efficiency in solvent systems based on a robust experimental quantification protocol and enthalpy data]]></article-title>
<source><![CDATA[Holzforschung]]></source>
<year>2019</year>
<volume>73</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1103-12</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manali]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[PrajapataShital]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[ButaniaMukesh]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gohel]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Liquisolid: A promising technique to improve dissolution efficiency and bioavailability of poorly water soluble nimodipine]]></article-title>
<source><![CDATA[J Drug Deliv Sci Technol]]></source>
<year>2019</year>
<volume>53</volume>
<page-range>1773-2247</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
